AFFX Affymetrix, Inc.

Affymetrix Inc. (NASDAQ:AFFX) announced today the launch of the Affymetrix UserForum, an online magazine featuring weekly updates on new technology, analyses, services, and training. The magazine will help scientists perform fast and successful GeneChip(R) microarray experiments. The UserForum provides an interactive community where Affymetrix customers can learn about new products and services, explore emerging applications, and share research challenges and success stories. The website offers feature articles, video interviews, and live web talks with interactive question-and-answer sessions. Topics covered include software tools, third-party providers, and collaboration updates, such as the 500K Control Program. "Affymetrix microarray users will learn about the very latest tools and applications that can help them plan and perform their GeneChip-based research in the lab," said Bronwyn Barnett, managing editor of UserForum. "The UserForum focuses on the whole product solution from the initial study design to the final data analysis. The content will help accelerate discovery by enabling customers to quickly select the right tools and services for the job." UserForum is a sister publication to the Affymetrix Microarray Bulletin (AMB), a print and online magazine featuring interviews with scientists discussing their most recent discoveries based on microarray research. To visit the Affymetrix UserForum and to register for regular email updates, please visit: www.affymetrix.com/userforum/index.uf. Current UserForum articles and video interviews include: Collaboration to Create Control Cohort Databases for Affymetrix 500K Human Mapping Array Set Affymetrix is collaborating with researchers at the National Genome Research Network in Germany, GlaxoSmithKline, Erasmus MC, the Karolinska Institute, and others to create a new publicly available control cohort database for the Affymetrix 100K and 500K Human Mapping Array sets. To watch this UserForum video, please visit: www.affymetrix.com/userforum/news/collaborations/schreiber.uf The Broad Institute's Mark Daly Discusses the Haploview Software Tool for Association Studies Mark Daly, Ph.D., and his team at the Broad Institute have developed a new software program, called Haploview, for analyzing linkage disequilibrium and haplotype patterns in genotype data sets comprising up to tens of thousands of SNPs in thousands of individuals. To watch this UserForum video, please visit: www.affymetrix.com/userforum/analysis/statistics/daly1.uf Duke and Affymetrix Sign Five-Year Translational Medicine Agreement Duke's Joe Nevins and Geoff Ginsburg outline their formula for translational medicine success. To read this UserForum article, please visit: www.affymetrix.com/userforum/news/collaborations/duke.uf About AMB AMB is an online and print magazine published by Affymetrix that highlights leading microarray research and diagnostic development from around the world. AMB features interviews by and for scientists, statisticians and software engineers--one expert interviewing another. Our goal is to create a forum where this community can discuss research and share new resources and information. AMB print and video interviews, as well as archived scientific seminars, can be found at: www.microarraybulletin.com. About Affymetrix Affymetrix scientists invented the world's first microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip(R) technology has become the industry standard in molecular biology research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and nearly 4,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with subsidiaries in Europe and Asia, as well as manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company has about 1,000 employees worldwide. For more information about Affymetrix, please visit the company's Web site at www.Affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies," or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: uncertainties relating to the success of the UserForum magazine and publication initiatives discussed in this press release; risks of the Company's ability to achieve and sustain higher levels of revenue, higher gross margins, reduced operating expenses; uncertainties relating to technological approaches, manufacturing (including risks related to the Company's ability to achieve hoped-for manufacturing yields for certain array products, including the ability to identify and resolve manufacturing problems), product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix' Form 10-K for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are registered trademarks owned or used by Affymetrix Inc.